AG 858

Drug Profile

AG 858

Alternative Names: HSPPC-70-C

Latest Information Update: 04 Jul 2007

Price : $50

At a glance

  • Originator Antigenics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Cancer therapeutic trials sections
  • 02 Nov 2005 Antigenics has expanded enrolment in a phase II trial for chronic myeloid leukaemia in the US and UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top